Background: Chronic kidney disease (CKD) presents a major global health challenge due to ineffective therapies against progressive renal fibrosis. Baricitinib, a selective JAK1/JAK2 inhibitor, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback